165 related articles for article (PubMed ID: 29650823)
1. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab].
Hasegawa J; Noura S; Hirota M; Matsumura T; Yasuyama A; Takata A; Koga C; Murakami M; Kameda C; Oda N; Kawabata R; Morishima H; Shimizu J; Matsunami N
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2289-2291. PubMed ID: 28133298
[TBL] [Abstract][Full Text] [Related]
3. [A Case of Rectal Cancer with Unresectable Liver Metastasis Responding to Rechallenge with FOLFIRI].
Kamiya M; Yoneyama K; Doi Y; Shirai J; Suzuki Y; Hatori S; Yamada T; Sato T; Yamamoto N; Oshima T; Yukawa N; Yoshikawa T; Rino Y; Masuda M
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2277-2279. PubMed ID: 28133294
[TBL] [Abstract][Full Text] [Related]
4. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
Fujii H; Matsuhashi N; Kitahora M; Takahashi T; Hirose C; Iihara H; Yamada Y; Watanabe D; Ishihara T; Suzuki A; Yoshida K
Oncologist; 2020 Mar; 25(3):e469-e476. PubMed ID: 32162797
[TBL] [Abstract][Full Text] [Related]
6. Prospective Multicenter Phase II Study of Biweekly TAS-102 and Bevacizumab for Metastatic Colorectal Cancer.
Ishizaki T; Mazaki J; Enomoto M; Shigoka M; Kasahara K; Matsudo T; Kawakita H; Nagakawa Y; Katsumata K; Tsuchida A
Anticancer Res; 2021 Apr; 41(4):2157-2163. PubMed ID: 33813427
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.
Watanabe D; Fujii H; Ohata K; Iihara H; Makiyama A; Kobayashi R; Hirose C; Hishida S; Matsuoka S; Tajima JY; Kiyama S; Takahashi T; Suzuki A; Matsuhashi N
BMC Cancer; 2023 Nov; 23(1):1078. PubMed ID: 37940878
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts.
Tsukihara H; Nakagawa F; Sakamoto K; Ishida K; Tanaka N; Okabe H; Uchida J; Matsuo K; Takechi T
Oncol Rep; 2015 May; 33(5):2135-42. PubMed ID: 25812794
[TBL] [Abstract][Full Text] [Related]
9. Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Matsuoka S; Fujii H; Iihara H; Ohata K; Hirose C; Watanabe D; Sadaka S; Kiyama S; Makiyama A; Takahashi T; Kobayashi R; Matsuhashi N; Suzuki A
Anticancer Res; 2023 May; 43(5):2351-2357. PubMed ID: 37097664
[TBL] [Abstract][Full Text] [Related]
10. Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Hamauchi S; Yamazaki K; Masuishi T; Kito Y; Komori A; Tsushima T; Narita Y; Todaka A; Ishihara M; Yokota T; Tanaka T; Machida N; Kadowaki S; Fukutomi A; Ura T; Onozawa Y; Ando M; Tajika M; Muro K; Yasui H; Mori K; Taniguchi H
Clin Colorectal Cancer; 2017 Mar; 16(1):51-57. PubMed ID: 27522626
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer.
Arita S; Shirakawa T; Matsushita Y; Shimokawa HK; Hirano G; Makiyama A; Shibata Y; Tamura S; Esaki T; Mitsugi K; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2016 Apr; 36(4):1959-66. PubMed ID: 27069187
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A
Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903
[TBL] [Abstract][Full Text] [Related]
13. TAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer.
Narihiro S; Suwa K; Ushigome T; Ohtsu M; Ryu S; Shimoyama Y; Okamoto T; Yanaga K
In Vivo; 2018; 32(6):1643-1646. PubMed ID: 30348728
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Masuishi T; Taniguchi H; Hamauchi S; Komori A; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Clin Colorectal Cancer; 2017 Jun; 16(2):e15-e22. PubMed ID: 27670892
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
[TBL] [Abstract][Full Text] [Related]
18. Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
Yoshida N; Kuriu Y; Ikeda J; Kudou M; Kirishima T; Okayama T; Miyagawa K; Takagi T; Nakanishi M; Doi T; Ishikawa T; Itoh Y; Otsuji E
Int J Clin Oncol; 2023 Oct; 28(10):1378-1387. PubMed ID: 37578664
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Scagliotti G; Nishio M; Satouchi M; Valmadre G; Niho S; Galetta D; Cortinovis D; Benedetti F; Yoshihara E; Makris L; Inoue A; Kubota K
Lung Cancer; 2016 Oct; 100():20-23. PubMed ID: 27597276
[TBL] [Abstract][Full Text] [Related]
20. [The toxicity profile of TAS-102. Practical considerations about neutropenia.].
Zaniboni A
Recenti Prog Med; 2019; 110(7):325-329. PubMed ID: 31379366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]